Adheris Health Revenue Falls but Cost Cuts and Platform Upgrades Aim at Q4 Cash Break-Even

MedAdvisor Limited ( (AU:AHE) ) has provided an update.

Adheris Health reported Q3 FY26 operating revenue of $5.4 million, down 23.9% year on year, with gross profit falling to $2.1 million and gross margin slipping to 39.7% amid weaker customer renewals, smaller deal sizes and pharma budget pressures. Net operating cash outflow was $4.6 million, but the company ended the period with $9.4 million in net cash, boosted by a $6.1 million holdback payment from the prior sale of its ANZ business, and it continues to target cashflow break-even in Q4 FY26.

Management has accelerated cost-reduction measures that are already lowering staff and corporate costs, while simultaneously rolling out significant upgrades to its new technology platform to improve program precision, configurability and digital capabilities. These enhancements are expected to shorten sales and implementation cycles, reduce delivery costs and underpin revenue diversification, positioning Adheris Health to stabilise margins and strengthen its commercial offering despite current revenue headwinds.

The most recent analyst rating on (AU:AHE) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:AHE Stock Forecast page.

More about MedAdvisor Limited

Adheris Health Limited, listed on the ASX, operates in the healthcare technology and patient engagement sector, providing digital platforms and programs that support pharmaceutical clients. The company focuses on technology-enabled adherence and communication solutions for pharma manufacturers, using its recently launched platform and products such as THRiV to deliver targeted digital programs.

Average Trading Volume: 377,103

Technical Sentiment Signal: Sell

Current Market Cap: A$12.75M

Find detailed analytics on AHE stock on TipRanks’ Stock Analysis page.